Minerva Neurosciences, Inc.
Minerva Neurosciences to Report First Quarter 2017 Financial Results and Business Updates on May 4, 2017
Management to host conference call
WALTHAM, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2017 on Thursday, May 4, 2017. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 2971783. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 30 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com .
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Venanpri Group23.3.2018 12:01 | pressemeddelelse
Agrisolutions Acquires Trinity
Crown Bioscience Inc.22.3.2018 14:45 | pressemeddelelse
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody
SEMAFO Inc.22.3.2018 12:01 | pressemeddelelse
SEMAFO: Construction of Boungou Mine 87% Complete
3Gtms21.3.2018 15:02 | pressemeddelelse
3Gtms Positioned in the Niche Players Quadrant of the Gartner Magic Quadrant for Transportation Management Systems
Addivant21.3.2018 14:39 | pressemeddelelse
Addivant Announces Price Increases on Hindered Amine Light Stablizers
VistaJet Ltd21.3.2018 14:19 | pressemeddelelse
VistaJet Connects Customers and Their Passions With the Global British Polo Day Tour
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum